Regalis Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.20 M
as on 17-07-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -16.87%
(FY 2022)
- Profit -45.29%
(FY 2022)
- Ebitda -34.30%
(FY 2022)
- Net Worth 59.97%
(FY 2022)
- Total Assets -68.96%
(FY 2022)
About Regalis Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Ashish Chopda, Rishabh Chopda, and Komal Chopda serve as directors at the Company.
- CIN/LLPIN
U24304CT2016PTC007375
- Company No.
007375
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chhattisgarh
Industry
Company Details
- Location
Raipur, Chattisgarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Regalis Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Chopda  | Director | 12-Oct-2019 | Current |
| Rishabh Chopda | Director | 12-Oct-2019 | Current |
| Komal Chopda | Director | 05-Jul-2016 | Current |
Financial Performance of Regalis Life Sciences.
Regalis Life Sciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 16.87% decrease. The company also saw a substantial fall in profitability, with a 45.29% decrease in profit. The company's net worth Soared by an impressive increase of 59.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regalis Life Sciences?
In 2021, Regalis Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aspire Pharmaceuticals Private LimitedActive 4 years 1 monthAshish Chopda and Rishabh Chopda are mutual person
- Rishabh Laboratories Pvt LtdActive 30 years 11 months
Ashish Chopda, Rishabh Chopda and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Regalis Life Sciences?
Unlock and access historical data on people associated with Regalis Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regalis Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regalis Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
